Combioxin SA

Combioxin SA, public limited company in Epalinges (VD), research. Registration active in the commercial register since 2015. Latest publication: July 28, 2022. UID CHE-310.572.972.

Combioxin is a clinical-stage biotechnology company dedicated to developing first-in-class drugs for critically ill patients. Its pipeline includes CAL02, an anti-virulence agent under development for severe community-acquired bacterial pneumonia, and an approach to acquired immune deficiency in critically ill patients.¹

Commercial register

Legal form: Public limited company
Registered office: Route de la Corniche 8, 1066 Epalinges
Share capital: CHF 195,000
UID: CHE-310.572.972
Registered since: 2015
Registered purpose (original language): Recherche, identification, développement, exploitation et commercialisation de technologies biomédicales pour le traitement et le diagnostic de maladies infectieuses (cf. statuts pour but complet). Show moreShow less

All 17 companies registered at this address

Similar companies

Apridami SA La Chaux-de-Fonds Computer programming, consultancy and related activities
OLGRAM SA Plan-les-Ouates Scientific research and development
Debiopharm Research & Manufacturing SA Martigny
BioXpress Therapeutics SA Monthey Scientific research and development
Debiopharm International SA Lausanne Manufacture of basic pharmaceutical products
Signal26 Biotherapeutics SA Epalinges Manufacture of basic pharmaceutical products

A free account opens every company that looks like Combioxin SA, and what they have in common. Create a free account

Register publications

The commercial register publishes each notice only in the language of the registry office concerned, and Prospex reproduces it unchanged.

Address changed July 28, 2022

Combioxin SA, à Epalinges, CHE-310.572.972 (FOSC du 17.06.2021, p. 0/1005220756). Nouvelle adresse: Route de la Corniche 8, 1066 Epalinges.
Address changed · Seat moved June 17, 2021

Combioxin SA, à Genève, CHE-310.572.972 (FOSC du 16.03.2020, p. 0/1004853747). Par suite du transfert de son siège à Epalinges, la société est inscrite au registre du commerce du canton de Vaud; par conséquent, elle est radiée d'office du registre de Genève.
Address changed · Seat moved June 17, 2021

Combioxin SA, précédemment à Genève, CHE-310.572.972 (FOSC du 16.03.2020, p. 0/1004853747). Statuts modifiés le 01.06.2021. Siège transféré à Epalinges. Nouvelle adresse: Route de la Corniche 5, 1066 Epalinges.
Capital increased Feb. 11, 2020

Combioxin SA, à Genève, CHE-310.572.972 (FOSC du 29.01.2018, p. 0/4019971). Augmentation ordinaire du capital-actions porté de CHF 187'500 à CHF 195'000 par l'émission de 75'000 actions de CHF 0.10, nominatives. Capital-actions: CHF 195'000, entièrement libéré, divisé en 1'950'000 actions de CHF 0.10, nominatives. Statuts modifiés le 29.01.2020.

Source: Swiss Official Gazette of Commerce (FOSC).

¹ This information was estimated by machine learning and may contain errors.